• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本血脂异常和心血管疾病高危患者采用初始他汀类单药治疗的低密度脂蛋白胆固醇目标达标率:一项回顾性数据库分析。

Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan - A Retrospective Database Analysis.

机构信息

Department of Medical Affairs, MSD K.K.

Center for Observational and Real-world Evidence, MSD Ltd.

出版信息

Circ J. 2018 May 25;82(6):1605-1613. doi: 10.1253/circj.CJ-17-0971. Epub 2018 Apr 7.

DOI:10.1253/circj.CJ-17-0971
PMID:29628458
Abstract

BACKGROUND

To understand the recent management status in Japan, we determined the low-density lipoprotein cholesterol (LDL-C) goal attainment (GA) rate of patients initiating statin monotherapy for dyslipidemia.

METHODS AND RESULTS

Dyslipidemic patients undergoing either primary prevention with high cardiovascular risk or secondary prevention (defined by 2012 Japan Atherosclerosis Society Guidelines) were retrospectively analyzed from a hospital-based claims database. In both groups, the LDL-C levels and GA rates of patients treated with intensive or standard statin monotherapy for ≥4 weeks (January 2012-August 2016) were evaluated. Among 1,501,013 dyslipidemic patients, 11,695 and 9,642 were included in the primary and secondary prevention groups, respectively. A total of 94% of patients underwent statin monotherapy as the initial lipid-lowering therapy, of which most (≥80%) took intensive statins. The proportions of patients in the primary prevention group who achieved an LDL-C goal <120 mg/dL by intensive and standard statins were 81.1% and 61.2%, respectively, and the proportions of those who achieved a goal <100 mg/dL in the secondary prevention group were 73.3% and 48.1%, respectively. The GA rates were similar regardless of disease complications.

CONCLUSIONS

Most patients (>70%) in both groups achieved LDL-C management goals using intensive statin monotherapy. Further treatment approaches are required for high-risk patients not achieving LDL-C goals by initial statin monotherapy. Continuous efforts are crucial for adherence and persistence of lipid-lowering therapies.

摘要

背景

为了了解日本的最新管理现状,我们确定了因血脂异常开始他汀类药物单药治疗的患者的低密度脂蛋白胆固醇(LDL-C)目标达标率(GA)。

方法和结果

从医院的索赔数据库中回顾性分析了接受高心血管风险一级预防或二级预防(根据 2012 年日本动脉粥样硬化学会指南定义)的血脂异常患者。在这两组患者中,评估了接受强化或标准他汀类药物单药治疗≥4 周(2012 年 1 月至 2016 年 8 月)的患者的 LDL-C 水平和 GA 率。在 1501013 名血脂异常患者中,分别有 11695 名和 9642 名患者被纳入一级和二级预防组。94%的患者接受他汀类药物单药治疗作为初始降脂治疗,其中大多数(≥80%)服用强化他汀类药物。在一级预防组中,接受强化和标准他汀类药物治疗后 LDL-C 目标<120mg/dL 的患者比例分别为 81.1%和 61.2%,而在二级预防组中,这一比例分别为 73.3%和 48.1%。无论疾病并发症如何,GA 率都相似。

结论

两组患者中超过 70%的患者通过强化他汀类药物单药治疗达到 LDL-C 管理目标。对于初始他汀类药物单药治疗未能达到 LDL-C 目标的高危患者,需要进一步的治疗方法。对于降脂治疗的依从性和持久性,持续的努力至关重要。

相似文献

1
Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan - A Retrospective Database Analysis.日本血脂异常和心血管疾病高危患者采用初始他汀类单药治疗的低密度脂蛋白胆固醇目标达标率:一项回顾性数据库分析。
Circ J. 2018 May 25;82(6):1605-1613. doi: 10.1253/circj.CJ-17-0971. Epub 2018 Apr 7.
2
Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.来自 3 个数据源的他汀类药物治疗患者的血脂异常患病率和血脂达标情况:一项回顾性分析。
J Am Heart Assoc. 2012 Dec;1(6):e001800. doi: 10.1161/JAHA.112.001800. Epub 2012 Dec 19.
3
Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan.在日本真实世界环境中,具有动脉粥样硬化性心血管疾病高危风险的患者实现低密度脂蛋白胆固醇目标的达标率。
J Atheroscler Thromb. 2023 Nov 1;30(11):1622-1634. doi: 10.5551/jat.63940. Epub 2023 Mar 16.
4
Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.与他汀类药物效力以及依折麦布/辛伐他汀联合疗法相关的治疗实践模式对高危心血管疾病患者低密度脂蛋白胆固醇(LDL-C)的降低作用
J Clin Lipidol. 2014 Jan-Feb;8(1):107-16. doi: 10.1016/j.jacl.2013.09.009. Epub 2013 Oct 1.
5
Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.美国接受他汀类药物治疗成年人中根据低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和载脂蛋白B划分的残余血脂异常:2009 - 2010年美国国家健康和营养检查调查
J Clin Lipidol. 2015 Jul-Aug;9(4):525-32. doi: 10.1016/j.jacl.2015.05.003. Epub 2015 May 16.
6
[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].[接受降脂治疗的血脂异常患者动脉粥样硬化性心血管疾病一级和二级预防中胆固醇目标达成情况:中国血脂异常防治研究(DYSIS-China)亚组分析]
Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Aug 24;44(8):665-70. doi: 10.3760/cma.j.issn.0253-3758.2016.08.006.
7
Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.根据 2016 年和 2019 年欧洲心脏病学会/欧洲动脉粥样硬化学会急性心肌梗死二级预防血脂异常指南评估低密度脂蛋白胆固醇达标率。
Rev Invest Clin. 2021 Nov 5;73(3):371-378. doi: 10.24875/RIC.21000152.
8
Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.美国高风险心血管疾病患者使用阿托伐他汀单一疗法进行现实世界治疗以降低低密度脂蛋白胆固醇(LDL-C)的局限性。
Vasc Health Risk Manag. 2014 Apr 25;10:237-46. doi: 10.2147/VHRM.S54886. eCollection 2014.
9
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.与他汀类单药治疗滴定相比,依折麦布联合辛伐他汀、阿托伐他汀或瑞舒伐他汀治疗时低密度脂蛋白胆固醇(LDL-C)水平的变化及目标达成情况。
Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.
10
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.改善他汀类药物治疗策略以降低 LDL 胆固醇:2 型糖尿病患者和非 2 型糖尿病患者达标相关因素。
Cardiovasc Diabetol. 2021 Jul 16;20(1):144. doi: 10.1186/s12933-021-01338-y.

引用本文的文献

1
Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan.日本血清脂蛋白(a)水平及其与动脉粥样硬化性心血管疾病的关联。
J Atheroscler Thromb. 2025 Apr 1;32(4):421-438. doi: 10.5551/jat.64953. Epub 2024 Oct 5.
2
Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15.依洛尤单抗在日本患者中的疗效、安全性和药代动力学:ORION-15 研究结果。
J Atheroscler Thromb. 2024 Jun 1;31(6):876-903. doi: 10.5551/jat.64454. Epub 2024 Jan 14.
3
Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial.
K-924匹伐他汀/依折麦布固定剂量复方制剂治疗高胆固醇血症患者的长期疗效与安全性:一项III期、多中心、开放标签试验
J Atheroscler Thromb. 2024 Mar 1;31(3):288-305. doi: 10.5551/jat.64272. Epub 2023 Sep 16.
4
Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan.在日本真实世界环境中,具有动脉粥样硬化性心血管疾病高危风险的患者实现低密度脂蛋白胆固醇目标的达标率。
J Atheroscler Thromb. 2023 Nov 1;30(11):1622-1634. doi: 10.5551/jat.63940. Epub 2023 Mar 16.
5
Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial.匹伐他汀/依折麦布固定剂量复方制剂与匹伐他汀的疗效和安全性:III 期、双盲、随机对照试验。
J Atheroscler Thromb. 2023 Nov 1;30(11):1580-1600. doi: 10.5551/jat.64006. Epub 2023 Mar 11.
6
Evaluation of glycemic status among hypercholesterolemic patients on atorvastatin in a tertiary care hospital - A retrospective study.评价阿托伐他汀治疗的高胆固醇血症患者的血糖状态 - 一项回顾性研究。
Indian J Pharmacol. 2022 May-Jun;54(3):165-170. doi: 10.4103/ijp.ijp_943_20.
7
The Effectiveness of Target Low-Density Lipoprotein Cholesterol Achieved with Strict Management in Secondary Prevention of Long-Term Coronary Events in Japanese Patients.在日本患者长期冠状动脉事件二级预防中,严格管理所实现的目标低密度脂蛋白胆固醇的有效性。
Acta Cardiol Sin. 2021 Jan;37(1):65-73. doi: 10.6515/ACS.202101_37(1).20200716A.
8
Guanxinshutong Alleviates Atherosclerosis by Suppressing Oxidative Stress and Proinflammation in ApoE Mice.冠心舒通通过抑制载脂蛋白E基因敲除小鼠的氧化应激和促炎反应减轻动脉粥样硬化
Evid Based Complement Alternat Med. 2020 Sep 16;2020:1219371. doi: 10.1155/2020/1219371. eCollection 2020.
9
Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene.ABCG5 或 ABCG8 基因突变患者中依折麦布-阿托伐他汀联合治疗的有益作用。
Lipids Health Dis. 2020 Jan 4;19(1):3. doi: 10.1186/s12944-019-1183-4.